We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
LPL Financial
LPLA
$26.5B
| $7.79M | 0.06% |
35,821
-33,869
| -49% | -$6.78M |
|
277
Pacira BioSciences
PCRX
$1.04B
| $7.69M | 0.06% |
191,901
+12,000
| +7% | +$496K |
|
278
Tractor Supply
TSCO
$16.7B
| $7.64M | 0.06% |
172,885
-5,060
| -3% | -$232K |
|
279
Globus Medical
GMED
$10.6B
| $7.64M | 0.06% |
128,348
+48,774
| +61% | +$2.78M |
|
280
Sutro Biopharma
STRO
$398M
| $7.57M | 0.05% |
162,823
-23,255
| -12% | -$1.16M |
|
|
SPLK
281
DELISTED
Splunk Inc
SPLK
| $7.43M | 0.05% |
70,073
-15,969
| -19% | -$1.52M |
|
282
Illinois Tool Works
ITW
$81.9B
| $7.41M | 0.05% |
29,630
-22,466
| -43% | -$5.26M |
|
283
Zoetis
ZTS
$32.2B
| $7.4M | 0.05% |
42,965
-28,337
| -40% | -$4.9M |
|
284
Kura Oncology
KURA
$901M
| $7.32M | 0.05% |
691,422
-122,942
| -15% | -$1.45M |
|
285
AT&T
T
$167B
| $7.25M | 0.05% |
454,660
| – | – |
|
286
Blackrock
BLK
$165B
| $7.15M | 0.05% |
10,344
-853
| -8% | -$571K |
|
287
Simon Property Group
SPG
$75.1B
| $6.99M | 0.05% |
60,544
-25,374
| -30% | -$2.76M |
|
|
AZPN
288
DELISTED
Aspen Technology Inc
AZPN
| $6.99M | 0.05% |
41,711
-23,220
| -36% | -$4.31M |
|
|
MRSH
289
Marsh
MRSH
$87.5B
| $6.96M | 0.05% |
37,020
-26,819
| -42% | -$4.76M |
|
290
Twist Bioscience
TWST
$5.39B
| $6.84M | 0.05% |
334,360
+25,000
| +8% | +$375K |
|
291
DuPont de Nemours
DD
$18.9B
| $6.71M | 0.05% |
74,855
+18,303
| +32% | +$1.57M |
|
292
RenaissanceRe
RNR
$13.7B
| $6.7M | 0.05% |
35,922
-16,290
| -31% | -$3.24M |
|
293
Madrigal Pharmaceuticals
MDGL
$12.7B
| $6.7M | 0.05% |
+29,000
| New | +$7.85M |
|
294
Allstate
ALL
$67.3B
| $6.65M | 0.05% |
60,968
-171,886
| -74% | -$19.5M |
|
295
Cigna
CI
$77B
| $6.5M | 0.05% |
23,178
-20,387
| -47% | -$5.31M |
|
296
Avery Dennison
AVY
$12.5B
| $6.46M | 0.05% |
32,011
-6,036
| -16% | -$1.03M |
|
297
iShares MSCI India ETF
INDA
$6.77B
| $6.41M | 0.05% |
146,600
+9,540
| +7% | +$395K |
|
|
AMED
298
DELISTED
Amedisys
AMED
| $6.4M | 0.05% |
70,000
+44,440
| +174% | +$3.65M |
|
299
BILL Holdings
BILL
$4.47B
| $6.38M | 0.05% |
54,573
+49,216
| +919% | +$4.68M |
|
300
PACCAR
PCAR
$70.2B
| $6.37M | 0.05% |
76,189
-666
| -0.9% | -$49.3K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.